ATE397084T1 - Lentivirale verpackungskonstrukte - Google Patents

Lentivirale verpackungskonstrukte

Info

Publication number
ATE397084T1
ATE397084T1 AT02704755T AT02704755T ATE397084T1 AT E397084 T1 ATE397084 T1 AT E397084T1 AT 02704755 T AT02704755 T AT 02704755T AT 02704755 T AT02704755 T AT 02704755T AT E397084 T1 ATE397084 T1 AT E397084T1
Authority
AT
Austria
Prior art keywords
cell lines
lentiviral packaging
packaging constructs
lentiviral
present
Prior art date
Application number
AT02704755T
Other languages
English (en)
Inventor
Tianci Luo
Ivan Plavec
Michael Kaleko
Janet Douglas
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE397084T1 publication Critical patent/ATE397084T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Packages (AREA)
  • Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)
AT02704755T 2001-03-13 2002-03-13 Lentivirale verpackungskonstrukte ATE397084T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27527501P 2001-03-13 2001-03-13

Publications (1)

Publication Number Publication Date
ATE397084T1 true ATE397084T1 (de) 2008-06-15

Family

ID=23051582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02704755T ATE397084T1 (de) 2001-03-13 2002-03-13 Lentivirale verpackungskonstrukte

Country Status (10)

Country Link
US (4) US7070993B2 (de)
EP (2) EP1373536B9 (de)
JP (1) JP4413495B2 (de)
AT (1) ATE397084T1 (de)
CA (1) CA2439067C (de)
DE (1) DE60226852D1 (de)
ES (1) ES2307726T3 (de)
IL (2) IL157335A0 (de)
NZ (1) NZ527937A (de)
WO (1) WO2002072851A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) * 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
EP1395669B1 (de) * 2001-01-26 2009-07-22 Selexis S.A. Matrix-anheftungsregionen und verfahren zu deren verwendung
US7070993B2 (en) 2001-03-13 2006-07-04 Novartis Ag Lentiviral packaging constructs
CA2475101A1 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
PL1959011T3 (pl) 2003-10-24 2012-07-31 Selexis Sa Wysokowydajny transfer genu i ekspresja w komórkach ssaczych przez procedurę wielokrotnej transfekcji sekwencji regionu przylegania do macierzy
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2007109131A2 (en) * 2006-03-17 2007-09-27 Massachusetts Institute Of Technology Lentiviral vectors that provide improved expression and reduced variegation after transgenesis
EP2425001A4 (de) 2009-04-30 2012-11-14 Univ California Anti-hiv-kombinationsvektoren, targeting-vektoren und anwendungsverfahren
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
US20140011980A1 (en) * 2012-07-03 2014-01-09 Allergan, Inc. Methods for sterilizing compositions and resulting compositions
WO2014026053A1 (en) 2012-08-09 2014-02-13 The Regents Of The University Of California Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
CN107530427A (zh) 2015-03-27 2018-01-02 南加利福尼亚大学 针对用于实体肿瘤的治疗的lhr的car t细胞疗法
GB201509040D0 (en) * 2015-05-27 2015-07-08 Oxford Genetics Ltd Cell lines
EP3302559B1 (de) 2015-06-04 2022-01-12 University of Southern California Auf lym-1 und lym-2 abgerichtete car-zellen-immuntherapie
KR20180053744A (ko) 2015-09-23 2018-05-23 사이토이뮨 테라퓨틱스 엘엘씨 면역 요법을 위한 flt3 유도된 car 세포
BR112019021022A2 (pt) 2017-04-07 2020-06-09 Uti Lp ensaio para medir a potência de interações receptor-ligante em nanomedicamentos
CA3092794A1 (en) 2018-03-01 2019-09-06 University Of Kansas Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
IL277773B2 (en) 2018-04-18 2026-05-01 Summa Health Compositions and methods for treating ischemia and cardiomyopathy
MX2021002316A (es) 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
US11912986B2 (en) 2019-09-23 2024-02-27 The Regents Of The University Of California Methods for screening genetic perturbations
JP2023522330A (ja) 2020-04-17 2023-05-30 シティ・オブ・ホープ Ｆｌｔ３陽性悪性腫瘍を処置するためのｆｌｔ３標的化キメラ抗原受容体改変細胞
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
GB202102832D0 (en) * 2021-02-26 2021-04-14 Ip2Ipo Innovations Ltd Retroviral vectors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5380830A (en) 1989-09-18 1995-01-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molecular clones of bovine immunodeficiency-like virus
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
EP0746625B1 (de) 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5888774A (en) 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
AU718551B2 (en) 1996-06-06 2000-04-13 Novartis Ag Vectors comprising SAR elements
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
EP0981636B1 (de) 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Auf lentivirus basierende gentransfer-vektoren
US6004798A (en) 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318575A1 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US6958226B1 (en) * 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
WO2001044458A2 (en) 1999-12-14 2001-06-21 Novartis Ag Bovine immunodeficiency virus (biv) based vectors
US6864085B2 (en) * 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
US20110097709A1 (en) 2000-03-13 2011-04-28 Kidd Geoffrey L Method for modifying a nucleic acid
NZ523649A (en) 2000-07-18 2005-02-25 Novartis Ag Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
US7070993B2 (en) * 2001-03-13 2006-07-04 Novartis Ag Lentiviral packaging constructs
CA2475101A1 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system

Also Published As

Publication number Publication date
US7442551B2 (en) 2008-10-28
EP1373536A2 (de) 2004-01-02
US20080268522A1 (en) 2008-10-30
US7070993B2 (en) 2006-07-04
EP1967590A3 (de) 2008-09-17
ES2307726T3 (es) 2008-12-01
NZ527937A (en) 2005-03-24
US7700342B2 (en) 2010-04-20
US20030054548A1 (en) 2003-03-20
WO2002072851A2 (en) 2002-09-19
JP2004523242A (ja) 2004-08-05
CA2439067C (en) 2011-02-15
IL185142A0 (en) 2009-02-11
US20080021207A1 (en) 2008-01-24
EP1373536B9 (de) 2009-09-02
JP4413495B2 (ja) 2010-02-10
AU2002238584B2 (en) 2006-02-23
EP1967590A2 (de) 2008-09-10
WO2002072851A3 (en) 2003-10-30
IL157335A0 (en) 2004-02-19
DE60226852D1 (de) 2008-07-10
CA2439067A1 (en) 2002-09-19
EP1373536B1 (de) 2008-05-28
US20070010017A1 (en) 2007-01-11
US8183356B2 (en) 2012-05-22

Similar Documents

Publication Publication Date Title
IL185142A0 (en) Lentiviral packaging constructs
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
TW200611910A (en) Interferon-alpha polypeptides and conjugates
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
MY142777A (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
CY1105772T1 (el) Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια
CY1112101T1 (el) Νευροτροφικοι παραγοντες
BRPI0412401A (pt) polipeptìdeos da amilase exoespecìficos, ácidos nucléicos que codificam tais polipeptìdeos e usos dos mesmos
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DE602004013372D1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
AU144678S (en) Bottle
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
WO2000005367A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
NO992916L (no) Fosfodiesterase 8A
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
NO20031860L (no) Kahalalid F
ATE557034T1 (de) Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen
AU2003259750A8 (en) Methods and compositions for targeting secretory lysosomes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1373536

Country of ref document: EP